{"schema_version":"secwatch.filing_event.v1","accession":"0001636282-25-000091","form_type":"8-K","ticker":"SYRE","cik":"0001636282","company_name":"Spyre Therapeutics, Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.534700+00:00","generated_at":"2026-05-17T20:45:28.560088+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Spyre Q2 net loss $36.7M; cash $526.6M; initiates Phase 2 SKYLINE-UC; TL1A data positive","bullets":["Net loss of $36.7M for Q2 2025 ($38.8M in Q2 2024); stock-based compensation $9.4M.","Cash, equivalents, and marketable securities of $526.6M as of June 30, 2025; expected runway into H2 2028.","R&D expense rose to $40.1M from $32.6M YoY on higher clinical trial costs; recognized $10.0M gain on sale of legacy asset pegzilarginase.","Positive interim Phase 1 data for two anti-TL1A antibodies (SPY002/SPY072): well-tolerated, PK supports Q3M/Q6M dosing, full TL1A engagement to 20 weeks.","Initiated Phase 2 SKYLINE-UC platform in May; on track to start Phase 2 SKYWAY-RD basket study in Q3 2025; SPY003 Phase 1 data expected Q4 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001636282-25-000091","json":"https://secwatch.observer/filing/0001636282-25-000091.json","markdown":"https://secwatch.observer/filing/0001636282-25-000091.md","text":"https://secwatch.observer/filing/0001636282-25-000091.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636282/000163628225000091/0001636282-25-000091-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636282/000163628225000091/syre-20250805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:45:28.560088+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}